Glenmark Gets Four-Month Jump On Generic Zetia Market Under Patent Settlement
This article was originally published in PharmAsia News
Executive Summary
Glenmark Pharmaceuticals will be able to launch its generic version of Merck's Zetia (ezetimibe) four-and-a-half months before the basic compound patent expires, under a settlement of a patent infringement suit with Merck
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)